FY2025 · ended Dec 31, 2025 · Revenue $797,244, +10301.1% YoY · Filed Mar 31, 2026
BioCorRx Inc. (BICX) files with the SEC under industry code 8093, Services-Specialty Outpatient Facilities, NEC. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $797,244 and a net loss of $3.4 million. As of Jun 30, 2026 it held $21,237 in cash and investments and $137,869 in total debt.
Revenue (TTM)
$651,145
+107.9% vs year-ago TTM
Net income (TTM)
$-3.28M
+30.7% vs year-ago TTM
Operating cash flow (TTM)
$-2.36M
-65.8% vs year-ago TTM
Free cash flow
$-2.04M
+42.3% vs prior year
EPS (TTM)
$-0.14
+51.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
26.40M
+64.0% vs prior year
Net cash
$-116,632
as of Jun 30, 2026
Operating margin
-775.9%
FY 2026
Company profile
- Industry
- Services-Specialty Outpatient Facilities, NEC (SIC 8093)
- Listed as
- BICX (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Anaheim, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1443863
- Former names
- FRESH START PRIVATE MANAGEMENT, INC. (until Feb 4, 2014); Cetrone Energy CO (until Nov 15, 2010)
Other Services-Specialty Outpatient Facilities, NEC companies
- Concentra Group Holdings Parent, Inc. CON
- Acadia Healthcare Company, Inc. ACHC
- Elite Health Systems Inc. EHSI
- Aesthetic Medical International Holdings Group Ltd PAIYY
All 5 Services-Specialty Outpatient Facilities, NEC companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $797,244 | $7,665 | $89,160 | $213,841 | $48,272 |
| Operating income | -$4.8M | -$5.1M | -$3.8M | -$4.7M | -$5.5M |
| Net income | -$3.4M | -$5.1M | -$3.8M | -$4.4M | -$5.2M |
| Diluted EPS | -$0.19 | — | — | — | — |
| Operating cash flow | -$2.3M | -$1.1M | -$1.9M | -$2.0M | -$3.5M |
| Free cash flow | — | — | — | -$2.0M | -$3.5M |
| Total assets | $2.1M | $385,941 | $388,887 | $766,594 | $819,975 |
| Total liabilities | $13.7M | $12.7M | $10.3M | $9.0M | $7.8M |
| Stockholders' equity | -$11.2M | -$12.1M | -$9.8M | -$8.1M | -$7.0M |
| Cash and investments | $139,360 | $88,033 | — | $113,135 | $130,358 |
| Total debt | $159,127 | $199,184 | $10,945 | $181,328 | $315,672 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Sep 4, 2026 | Aug 31, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 15, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Apr 2, 2026 | Mar 26, 2026 |
| 10-K | Annual report | Mar 31, 2026 | Dec 31, 2025 |
| 10-Q | Quarterly report | Nov 14, 2025 | Sep 30, 2025 |
All 499 BioCorRx Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.